Document:

Exhibit 10.1

 

 

[**] = Portions of this exhibit have been
omitted pursuant to a confidential treatment request.

An unredacted version of this exhibit has
been filed separately with the Commission.

 

Amendment No. 2

To the

LICENSE AGREEMENT

 

This Amendment is effective as of September
1, 2015 and amends the License Agreement dated as of July 5, 2007 (as previously amended, the “Agreement”), by and
between Wyeth Holdings LLC (formerly known as Wyeth Holdings Corporation, “Wyeth”), and Novavax, Inc. (“Novavax”).

 

Novavax has entered into a joint venture,
CPL Biologics Ltd. (the “JV”), with Cadila Pharmaceuticals Limited to develop and commercialize certain products in
India whereby Novavax took a minority equity position in the JV and Novavax has granted certain sublicenses under the Agreement
to the JV for India only (the “Sublicenses”). Novavax and Wyeth desire to amend the Agreement as set forth below in
connection with Novavax’s participation in the JV. Capitalized terms used but not defined herein shall have the meanings
set forth in the Agreement.

 

Each of Wyeth and Novavax hereby agrees
as follows:

 

		1.	The parties acknowledge and agree that, prior to the date hereof, Novavax has terminated the Agreement
with respect to [**], and accordingly as of the date here, “Indication” means each of Pandemic Flu and Seasonal Flu.

 

		2.	Prior to the date hereof Novavax has provided to Wyeth a true and complete copy of the Sublicenses
as required by Section 2.2.3 of the Agreement. Novavax represents and warrants to Wyeth that neither Novavax nor any of its affiliates
has received or has a right to receive any payment or any other consideration for the grant of the Sublicense to the JV or for
the establishment of the JV and the contributions thereto by Novavax or its Affiliates, other than the issuance to Novavax of ownership
shares in the JV and the future payment of cash dividends and distributions to Novavax as holder of such ownership shares. Based
on the preceding sentence, Wyeth acknowledges that it is not entitled under Section 2.2.3 of the Agreement to any portion of such
ownership shares or such future dividends or distributions.

 

		3.	Wyeth acknowledges that Novavax has granted the Sublicenses to the JV. Novavax hereby represents
and warrants to Wyeth that the JV is currently developing under the Sublicenses (a) a certain monovalent H1N1 vaccine (the “Monovalent
JV Product”) for Seasonal Flu and (b) a certain trivalent influenza vaccine (the “Trivalent JV Product” and,
together with the Monovalent JV Product, the “JV Products”) for Seasonal Flu, in each case for [**] in India. Novavax
represents and warrants to Wyeth that (a) neither the Monovalent JV Product nor the Trivalent JV Product is currently being developed
or studied for Pandemic Flu in any country and (b) the JV is not currently developing or studying any other Product for Pandemic
Flu. The JV Products are “Products” for purposes of the Agreement. Novavax further represents and warrants to Wyeth
that the JV is not currently developing a quadrivalent influenza vaccine.

 

     

    
[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with the Commission.

    

 

		4.	The parties acknowledge that (a) Novavax has already paid to Wyeth the milestone payments set forth
in Sections 3.1.3.1 and 3.1.3.2 of the Agreement with respect to a Product for Seasonal Flu, (b) Novavax has informed Wyeth that
the JV has conducted a Phase III trial for the Monovalent JV Product for Seasonal Flu in India, (c) to date Novavax has not paid
any milestone payment pursuant to Section 3.1.3.3 of the Agreement for a Seasonal Flu Product, but as of the date hereof the milestone
payment under Section 3.1.3.3 of the Agreement is due, payable and overdue with respect to the Monovalent JV Product (such payment
with respect to the Monovalent JV Product, the “Overdue Phase III Payment”), and (d) Novavax has informed Wyeth that
the Monovalent JV Product has received [**] in India and may achieve [**] in India in the near future, at which time the milestone
payment under Section 3.1.3.4 of the Agreement will become due and payable with respect to the Monovalent JV Product.

 

		5.	Subject to the terms and conditions hereof, Wyeth and Novavax agree that payment of the Overdue
Phase III Payment, together with accrued and unpaid interest thereon under Section 3.4 of the Agreement, is waived and in lieu
thereof Novavax shall make payment to Wyeth as set forth in paragraph 5.1, 5.2, 5.3 or 5.4 below, as applicable:

 

		5.1.	If a Phase III trial of the Monovalent JV Product or any Product that is substantially the same
as the Monovalent JV Product (whether developed by Novavax or any of its Affiliates or sublicensees, such Product a “Similar
Monovalent Product”), or of the Trivalent JV Product or any Product that is substantially the same as the Trivalent JV Product
(whether developed by Novavax or any of its Affiliates or sublicensees, such Product a “Similar Trivalent Product”)
is commenced in any country other than India, and if initiation of such Phase III clinical trial (for purposes hereof, initiation
shall mean the first administration of such Product in such a trial) occurs on or prior to December 31, 2015, or if the Agreement
is terminated in its entirety or with respect to the Seasonal Flu Indication for any reason on or prior to December 31, 2015, then
in either case Novavax shall immediately pay to Wyeth [**];

 

		5.2.	If a Phase III trial of the Monovalent JV Product, any Similar Monovalent Product, the Trivalent
JV Product or any Similar Trivalent Product is commenced in any country other than India, and if initiation of such Phase III clinical
trial (for purposes hereof, initiation shall mean the first administration of such Product in such a trial) occurs on or after
January 1, 2016 but on or prior to December 31, 2016, or if the Agreement is terminated in its entirety or with respect to the
Seasonal Flu Indication for any reason on or after January 1, 2016 but on or prior to December 31, 2016, then in either case Novavax
shall immediately pay to Wyeth [**];

 

     

    
[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with the Commission.

    

 

		5.3.	If a Phase III trial of the Monovalent JV Product, any Similar Monovalent Product, the Trivalent
JV Product or any Similar Trivalent Product is commenced in any country other than India, and if initiation of such Phase III clinical
trial (for purposes hereof, initiation shall mean the first administration of such Product in such a trial) occurs on or after
January 1, 2017, or if the Agreement is terminated in its entirety or with respect to the Seasonal Flu Indication for any reason
on or after January 1, 2017, then in either case Novavax shall immediately pay to Wyeth [**]; and

 

		5.4.	If Novavax has not paid any amount to Wyeth pursuant to paragraph 5.1, 5.2 or 5.3 above prior to
December 31, 2017, then Novavax shall pay to Wyeth [**] on December 31, 2017. Notwithstanding the foregoing, Novavax may voluntarily
elect, at any time prior to December 31, 2017 to pay Wyeth the Overdue Phase III Payment in the amount specified in paragraph 5.1
if paid prior to December 31, 2015, paragraph 5.2 if on or after January 1, 2016 and on or before December 31, 2016 or paragraph
5.3 if paid on or after January 1, 2017.

 

For the avoidance of doubt,
termination of the Agreement in its entirety or with respect to the Seasonal Flu Indication for any reason shall not relieve Novavax
of the obligation to make a payment under paragraph 5.1, 5.2, 5.3 or 5.4 above, as applicable, regardless of whether a Phase III
Trial of the Monovalent JV Product, any Similar Monovalent Product, the Trivalent JV Product or any Similar Trivalent Product has
been initiated in any country other than India as of the date of termination, and such obligation to make payment to Wyeth shall
survive any termination of the Agreement.

 

		6.	Subject to the terms and conditions hereof, Wyeth and Novavax agree that the milestone payment
set forth in Section 3.1.3.4 of the Agreement shall not be triggered and become due and payable by the [**] of a JV Product in
India, but such milestone payment shall become payable upon [**] of a Product indicated for Seasonal Flu in any country other than
India. In consideration of the foregoing, Novavax shall make a one-time only payment of [**] to Wyeth within ten (10) days of the
effective date of this Amendment.

 

The Parties further agree for
each applicable year starting on July 5, 2015 that the annual license maintenance fee described in Section 3.1.2 of the Agreement
for the Indication of Seasonal Flu, and only that Indication, shall be $200,000 until the [**] of a Product for Seasonal Flu (other
than [**] in India as referred to above). The annual license maintenance fee for Pandemic Flu under Section 3.1.2 of the Agreement
is not affected by the foregoing. Accordingly, the total annual license maintenance fees for the period beginning July 5, 2015
is $300,000 under Section 3.1.2 of the Agreement. Wyeth hereby acknowledges that Novavax has paid $200,000 to Wyeth and will therefore
pay the additional $100,000 within ten (10) days of the effective date of this Amendment.

 

     

    
[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with the Commission.

    

 

		7.	Novavax hereby represents to Wyeth that, to the knowledge of Novavax, the JV does not currently
intend to market, sell or distribute the Monovalent JV Product and the Trivalent JV Product simultaneously long-term in India and
that the JV intends to replace the Monovalent JV Product with the Trivalent JV Product in the market in India over time. Accordingly,
subject to the terms and conditions hereof, if Novavax pays to Wyeth on a timely basis the payments required pursuant to paragraphs
5 and 6 of this Amendment No. 2 and if the JV discontinues all direct marketing, sales and distribution of the Monovalent JV Product
in India within 24 months after the [**] of the Trivalent JV Product in India, then Novavax shall not be obligated to make any
further payments with respect to the initiation of any clinical trial of the Trivalent JV Product in or for India or the [**] of
the Trivalent Product in India. For the purposes of this Amendment, the phrase “direct marketing, sales and distribution”
refers to activities undertaken by or on behalf of Novavax, its Affiliates, the JV or any of their respective sublicensees, distributors,
wholesalers, resellers or similar commercial collaborators.

 

		8.	Subject to paragraph 7 of this Amendment No. 2, the Parties understand that for the single Indication
of Seasonal Flu only, there may be multiple Seasonal Flu Products in development and subsequently offered for commercial sale by
Novavax or any of its Affiliates or sublicensees (e.g. a monovalent Seasonal Flu Product, a trivalent Seasonal Flu Product, a quadrivalent
Seasonal Flu Product, etc.). The Parties agree that the milestone payments set forth in Sections 3.1.3.1, 3.1.3.2, and 3.1.3.4
of the Agreement are deemed owed only on the first instance of any Seasonal Flu Product triggering such payment but may not be
owed in certain circumstances for any subsequent Seasonal Flu product or products subject to the following sentences of this paragraph
8. The Parties agree that the milestone payment set forth in Section 3.1.3.3 of the Agreement, described herein as the Overdue
Phase III Payment and owed by Novavax pursuant to the terms of Section 5 of this Amendment, shall be deemed applicable to the first
Phase III clinical trial of a Seasonal Flu Product. Notwithstanding the foregoing sentences of this paragraph 8, if in a particular
country other than India, Novavax or any of its Affiliates or sublicensees achieve a [**] of a Seasonal Flu Product (a “Prior
Seasonal Flu Product”), regardless of the number of influenza strains contained in such Seasonal Flu Product, and any of
them later introduces one or more additional Seasonal Flu Products in the same country (a “Later Seasonal Flu Product”),
regardless of the number of strains contained in such Seasonal Flu Product, Novavax shall pay to Wyeth the amount of $14 million,
which will be deemed payment of the Milestone Payments for the additional Seasonal Flu Product unless Novavax and its Affililates
and Sublicensees discontinue all marketing, sales and distribution of the Prior Seasonal Flu Product in that country within 24
months of [**] of the Later Seasonal Flu Product. For purposes of clarification, in the event that a Seasonal Flu Product is sold
in a country by Novavax or any of its Affiliates or sublicensees and any of these parties introduces an additional Seasonal Flu
Product in such country, unless all marketing, sales and distribution of any previously launched Seasonal Flu Product are discontinued
within 24 months of the [**] of the succeeding Seasonal Flu Product, then Novavax owes the $14M in Milestone Payments for the second
Seasonal Flu Product referred to above. Furthermore, this same principle applies for any subsequent Seasonal Flu Products and unless
the marketing, sales and distribution of any previously launched Seasonal Flu Product are discontinued within 24 months of the
[**] in the country of the next Seasonal Flu Vaccine, then a $14M milestone is owed for each additional Seasonal Flu Product that
achieves [**].

 

     

    
[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.
An unredacted version of this exhibit has been filed separately with the Commission.

    

 

		9.	As amended and supplemented hereby, the parties confirm that the Agreement remains in full force
and effect.

 

IN WITNESS HEREOF, the parties hereto have
caused their duly authorized representatives to execute this Amendment No. 2 to the Agreement.

 

	NOVAVAX, INC.	 	WYETH HOLDINGS LLC	 
	 	 	 	 	 	 
	 	 	 	 	 	 
	By:	/s/ John A. Herrmann	 	By:	/s/ Robert J. Smith	 
	 	 	 	 	 	 
	Name:	John A. Herrmann III	 	Name:	Robert J. Smith	 
	 	 	 	 	 	 
	Title:	SVP, General Counsel	 	Title:	Senior Vice PresidentEX-10-1

 Exhibit 10.1 

EMPLOYMENT AND NON-COMPETITION AGREEMENT 

(Scott Thompson) 
 THIS
EMPLOYMENT AND NON-COMPETITION AGREEMENT (the “Agreement”) is executed as of this 4th day of September, 2015 (referred to as the “Effective Date” or the “Date of Hire”), by and between Tempur
Sealy International Inc., a Delaware corporation (the “Company”), and Scott Thompson, an individual (“Employee”). 

In consideration of the mutual agreements and covenants contained herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged by the Company and Employee, it is hereby agreed as follows: 
 ARTICLE I 

EMPLOYMENT 
 1.1 Term of
Employment. Effective as of the Date of Hire, the Company agrees to employ Employee as an employee of the Company and as the Chairman, Chief Executive Officer and President of the Company as further set forth in Section 1.2, and Employee
accepts employment by the Company, for the period commencing on the Date of Hire and ending on December 31, 2018 (the “Initial Term”), subject to earlier termination as set forth in Article III below. Unless earlier terminated
in accordance with Article III, following the expiration of the Initial Term, this Agreement shall be automatically renewed for successive one-year periods (collectively, the “Renewal Terms”; individually, a “Renewal
Term”) unless, at least one hundred and twenty (120) days prior to the expiration of the Initial Term or the then current Renewal Term, either party provides the other party with a written notice of intention not to renew, in which
case the Employee’s employment with the Company, and the Company’s obligations hereunder, shall terminate as of the end of the Initial Term or said Renewal Term, as applicable. Except as otherwise expressly provided herein, the terms and
conditions of this Agreement during any Renewal Term shall be the same as the terms in effect immediately prior to such renewal, subject to any such changes or modifications as mutually may be agreed between the parties as evidenced in a written
instrument signed by both the Company and Employee. 
 1.2 Position and Duties. 

(a) From the Date of Hire through September 7, 2015 (the “Transition Period”), Employee shall be employed as an employee
of the Company. In his capacity as an employee, Employee shall be subject to the authority of, and shall report to, the Company’s Board of Directors. During the Transition Period, Employee shall be engaged in transition activities with respect
to the assumption of the Chairman, Chief Executive Officer and President positions. On the Effective Date the Employee shall be appointed to the Board of Directors. 

(b) Effective on the day after the Transition Period, Employee shall be employed in the position of Chief Executive Officer and President. In
such capacity, Employee shall be subject to the authority of, and shall report to, the Company’s Board of Directors. Employee shall devote Employee’s entire business time, loyalty, attention and energies exclusively to the business
interests of the 

 
Company while employed by the Company, and shall perform his duties and responsibilities diligently and to the best of his ability. Effective on the day after the Transition Period, Employee
shall be elected by the Board of Directors as Chairman. In addition, the Company shall nominate Employee to serve as a director in connection with any annual or special meeting of stockholders at which stockholders will vote on the election of
directors and, if elected as a director, the Board will elect Employee as Chairman. 
 (c) The Company may choose to have Employee be
classified as an employee of a subsidiary of the Company consistent with other members of management, and such treatment will be treated for purposes of this Agreement as employment by the Company, and will not relieve the Company of any of its
obligations under this Agreement. 
 ARTICLE II 

COMPENSATION AND OTHER BENEFITS 

2.1 Base Salary. The Company shall pay Employee an annual salary of $1,100,000 (“Base Salary”), payable in accordance
with the normal payroll practices of the Company. Employee’s Base Salary will be reviewed and be subject to adjustment by the Board of Directors or its Compensation Committee at their discretion each fiscal year in accordance with the
Company’s annual review policy, commencing with the fiscal year 2017. 
 2.2 Bonuses. (a) Employee will be eligible to earn
an annual performance-based bonus based on a formula approved by the Company’s Board of Directors or its Compensation Committee and incorporated herein by this reference for the full or pro rata portion of any fiscal year after
2015 during which Employee is employed by the Company (a “Bonus Year”), the terms and conditions of which, as well as Employee’s entitlement thereto, shall be determined annually in the sole discretion of the Company’s
Board of Directors or its Compensation Committee (the “Performance Bonus”). The amount of the Performance Bonus will vary based on the pro rata portion or full portion of the applicable Bonus Year during which Employee
is employed by the Company and the achievement of individual or Company performance criteria in the formula established by the Company’s Board of Directors or Compensation Committee. The formula will be set to target a Performance Bonus equal
to 125% of Base Salary as of the earlier of the date the Target Bonus terms are approved by the Board and March 25 of such year (the “Target Bonus”) if the performance criteria in the formula are met, and the actual bonus
awarded based on the performance criteria may be more or less than the Target Bonus, but not more than 200% of the Target Bonus. Any Performance Bonus due with respect to a Bonus Year will be paid on or before March 15 of the following calendar
year. 
 (b) For 2015, the Company will pay a bonus to Employee in the amount of $458,000 (the “2015 Bonus”), representing
a pro rata portion of 125% of his Base Salary payable for 2015. This 2015 Bonus will be paid on or before March 15, 2016. 

(c) The Company agrees to pay the Employee a cash signing bonus in the amount of $1.6 million, on or before September 15, 2015 (the
“Signing Bonus”). The Employee agrees that if prior to December 31, 2017 the Employee voluntarily terminates his employment, but not for Good Reason pursuant to Section 3.1(b), then within fifteen (15) days after such
termination he will repay to the Company a pro rata portion of the Signing Bonus, in the amount of $60,000 for each full month remaining in the period between the date of his termination and December 31, 2017. 

  
 2 

 2.3 Grants and Purchases of Equity. 

(a) Grant of Stock Options. On the Date of Hire, the Company will grant Employee non-qualified options to purchase 310,000 shares of
the Company’s Common Stock, par value $.01 per share (the “Common Stock”), pursuant to the form of stock option agreement attached as Exhibit A to this Agreement, with the grant price set at the fair market value on the
date of grant and subject to vesting in three equal annual installments (the “2015 Option Agreement”). 
 (b)
Subscription Agreement. The Employee and the Company will on the Date of Hire enter into a Subscription Agreement in the form of Exhibit B hereto (the “Subscription Agreement”) pursuant to which the Employee
will agree to purchase, and the Company will agree to sell, 69,686 shares of Common Stock (the “Purchased Shares”) at a price per share of $71.75 (representing the closing price of the Common Stock on the New York Stock Exchange on
the last trading day prior to the date of this Agreement). 
 (c) Stock Purchase Matching PRSU Award. As additional consideration
for Employee’s agreement to accept employment with the Company, on the Date of Hire the Company will issue Employee performance restricted stock units (“Matching PRSUs”) representing the total number of shares of the
Company’s Common Stock, par value $.01 per share (“Common Stock”), that Employee commits to purchase pursuant to the Subscription Agreement. The Matching PRSUs will be issued pursuant to a Restricted Stock Unit Agreement in the
form of Exhibit C hereto (the “Matching PRSU Agreement”) and vest over the next three (3) years in annual installments, subject to meeting the performance metric set forth in the Matching PRSU Agreement. 

(d) Project 650 Grant. On the Date of Hire, the Company will grant Employee performance restricted stock units for 620,000 shares of
the Company’s Common Stock pursuant to the form of Performance Restricted Stock Unit Agreement attached as Exhibit D to this Agreement (the “Project 650 PRSU Agreement”). 

(e) On the Date of Hire, the Company will issue Employee restricted stock units (“Base RSUs”) for 118,000 shares of the
Company’s Common Stock pursuant to the Restricted Stock Unit Agreement attached as Exhibit E to this Agreement (the “Base RSU Agreement”). 

(f) The Company anticipates that commencing in 2017 Employee will be considered for future equity awards in accordance with the
Company’s normal executive compensation practices, but the timing, amount and terms of any such future grants will be subject to the discretion of the Board of Directors or the Compensation Committee. 

2.4 Benefit Plans. Employee will be eligible to participate in the Company’s retirement plans that are qualified under
Section 401(a) of the Internal Revenue Code of 1986, as amended (the “Code”), and in the Company’s employee welfare benefit plans that are generally applicable to all executive employees of the Company (the
“Plans”), in accordance with the terms and 

  
 3 

 
conditions thereof. A summary of the Company’s Plans applicable to senior executives as currently in effect has been provided to Employee. In any event, the terms and conditions of the
Plans, as expressed in the Plan documents, will control including, but not limited to the Company’s ability to amend, modify or terminate any of those programs as it determines appropriate in accordance with the Plans’ terms. 

2.5 Expenses. The Company shall reimburse Employee for all expenses reasonably incurred in the course of the performance of
Employee’s duties and responsibilities pursuant to this Agreement and consistent with the Company’s policies with respect to travel, entertainment and miscellaneous expenses, and the requirements with respect to the reporting of such
expenses. 
 2.6 Financial Planning. Employee shall be eligible to participate in the Company’s executive financial planning
program which provides reimbursement of financial planning expenses to eligible executives in accordance with the terms of the program. 

2.7 Vacation. Employee shall be entitled to vacation in any calendar year in accordance with the Company’s general vacation
policies for senior executive employees. 
 2.8 Residence and Commuting. 

(a) The Company will reimburse the Employee for reasonable temporary housing costs in Lexington through December 31, 2015. Employee
agrees that he will maintain a secondary residence in Lexington, Kentucky commencing on or before December 31, 2015. The Employee agrees that he will relocate and establish Lexington, Kentucky as his primary residence by December 31, 2017.
The Company agrees to reimburse the Employee for his reasonable relocation costs in accordance with the Company’s relocation policy for senior executives. A copy of the Company’s current policy has been provided to the Employee. 

(b) The Employee will be responsible for the cost of commuting between his primary residence and Lexington until he relocates to Lexington as
described above. 
 2.9 Withholding. All payments to be made by the Company hereunder will be subject to any withholding
requirements. 
 2.10 Application of Policies. Employee acknowledges receipt of copies of the Company’s Policy on Insider
Trading and Confidentiality, Code of Business Conduct and Ethics, Stock Ownership Guidelines and Clawback Policy, and acknowledges that he is subject to the provisions of each such document. Employee further acknowledges and agrees that all amounts
paid hereunder and any equity awards granted pursuant to this Agreement will be subject to the terms of the Clawback Policy, and any amended clawback policy or replacement clawback policy adopted by the Board of Directors from time to time. 

  
 4 

 ARTICLE III 

TERMINATION 
 3.1 Right
to Terminate; Automatic Termination. 
 (a) Termination by Company Without Cause. Subject to Section 3.2, the Company may
terminate Employee’s employment and all of the Company’s future obligations under this Agreement at any time and for any reason. 

(b) Termination by Employee for Good Reason. Subject to Section 3.2, Employee may terminate his employment obligation hereunder
(but not his obligations under Article IV hereof) for “Good Reason” (as hereinafter defined) if Employee gives written notice thereof to the Company within thirty (30) days of the event he deems to constitute Good Reason (which notice
shall specify the grounds upon which such notice is given) and the Company fails, within thirty (30) days of receipt of such notice, to cure or rectify the grounds for such Good Reason termination set forth in such notice. If the Company fails
to cure or rectify the grounds for such Good Reason termination set forth in the notice provided above within thirty (30) days of receipt of such notice, then Employee may terminate his employment under this Section 3.1(b) any time within
thirty (30) days following such failure. “Good Reason” shall mean any of the following: (i) relocation of Employee’s principal workplace over sixty (60) miles from the Company’s existing workplaces without
the consent of Employee (which consent shall not be unreasonably withheld, delayed or conditioned), (ii) after the Transition Period, Employee is demoted from the position of Chief Executive Officer or President of the Company, (iii) after
the Transition Period, a material diminution in the Employee’s authority, duties or responsibilities as Chief Executive Officer and President of the Company, (iv) the Company fails to nominate Employee to serve as a director in connection
with any annual or special meeting of stockholders at which stockholders will vote on the election of directors or, if elected as a director, the Board fails to elect the Employee as Chairman, or (v) the Company’s material breach of this
Agreement which is not cured within thirty (30) days after receipt by the Company from Employee of written notice of such breach. 

(c) Termination by Company For Cause. Subject to Section 3.2, the Company may terminate Employee’s employment and all of the
Company’s obligations under this Agreement at any time “For Cause” (as defined below) by giving notice to Employee stating the basis for such termination, effective immediately upon giving such notice or at such other time thereafter
as the Company may designate. “For Cause” shall mean any of the following: (i) Employee’s willful and continued failure to substantially perform the reasonably assigned duties with the Company which are consistent with
Employee’s position and job description referred to in this Agreement, other than any such failure resulting from incapacity due to physical or mental illness, after a written notice is delivered to Employee by the Board of Directors of the
Company which specifically identifies the manner in which Employee has not substantially performed the assigned duties and allowing Employee thirty (30) days after receipt by Employee of such notice to cure such failure to perform,
(ii) material breach of this Agreement or any other written agreement between Employee and the Company which is not cured within thirty (30) days after receipt by Employee from the Company of written notice of such breach, (iii) any
material violation of any material written policy of the Company, (iv) Employee’s willful misconduct which is 

  
 5 

 
materially and demonstrably injurious to the Company, (v) Employee’s conviction by a court of competent jurisdiction of, or his pleading guilty or nolo contendere to, any felony, or
(vi) Employee’s commission of an act of fraud, embezzlement, or misappropriation against the Company or any breach of fiduciary duty or breach of the duty of loyalty, including, but not limited to, the offer, payment, solicitation or
acceptance of any unlawful bribe or kickback with respect to the Company’s business. For purposes of this paragraph, no act, or failure to act, on Employee’s part shall be considered “willful” unless done, or omitted to be done,
in knowing bad faith and without reasonable belief that the action or omission was in, or not opposed to, the best interests of the Company. Any act, or failure to act expressly authorized by a resolution duly adopted by the Board of Directors or
based upon the written advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, in good faith and in the best interests of the Company. Notwithstanding the foregoing, Employee shall not be deemed to have
been terminated For Cause unless and until there shall have been delivered to Employee a copy of a resolution, duly adopted by the Board of Directors at a meeting of the Board called and held for such purpose (after reasonable notice to Employee and
an opportunity for Employee, together with Employee’s counsel, to be heard before the Board at a duly called meeting at which a quorum is present), finding that in the good faith opinion of the Board of Directors Employee committed the conduct
set forth above in (i), (ii), (iii), (iv), (v) or (vi) of this Section 3.1(c) and specifying the particulars thereof in detail. 

(d) Termination Upon Death or Disability. Subject to Section 3.2, Employee’s employment and the Company’s obligations
under this Agreement shall terminate: (i) automatically, effective immediately and without any notice being necessary, upon Employee’s death; and (ii) in the event of the disability of Employee, by the Company giving notice of
termination to Employee. For purposes of this Agreement, “disability” means the inability of Employee, due to a physical or mental impairment, for ninety (90) days (whether or not consecutive) during any period of three hundred sixty
(360) days, to perform, with reasonable accommodation, the essential functions of the work contemplated by this Agreement. In the event of any dispute as to whether Employee is disabled, the matter shall be determined by the Company’s
Board of Directors in consultation with a physician selected by the Company’s health or disability insurer or another physician mutually satisfactory to the Company and Employee. Employee shall cooperate with the efforts to make such
determination or be subject to immediate discharge. Any such determination shall be conclusive and binding on the parties. Any determination of disability under this Section 3.1 is not intended to alter any benefits any party may be entitled to
receive under any long-term disability insurance policy carried by either the Company or Employee with respect to Employee, which benefits shall be governed solely by the terms of any such insurance policy. Nothing in this subsection shall be
construed as limiting or altering any of Employee’s rights under State workers compensation laws or State or federal Family and Medical Leave laws. 

3.2 Rights Upon Termination. 

(a) Section 3.1(a) (Termination by the Company Without Cause) and 3.1(b) (Termination by the Employee for Good Reason)
Terminations. If Employee’s employment terminates pursuant to Section 3.1(a) or 3.1(b) hereof, Employee shall have no further rights against the Company hereunder, except for the right to receive, subject to execution of a release
and waiver in the form 

  
 6 

 
customarily used by the Company in connection with the termination of other similarly situated senior executives (“Release and Waiver”) in the case of clauses (ii) -
(iv) and (vi) below, (i) any earned but unpaid Base Salary and the value of any accrued but unused vacation, (ii) payment of Base Salary for a period of two (2) years from the effective date of termination (the
“Severance Period”), payable in accordance with the normal payroll practices of the Company and reduced by any salary continuation benefit paid under any of the Plans maintained pursuant to Section 2.4, (iii) (x) any
previously earned Performance Bonus for a prior Bonus Year that has not been paid, and in the event of any termination after December 31, 2015 any 2015 Bonus that has not been paid, and (y) any annual Performance Bonus or 2015 Bonus due
for the calendar year of such termination pursuant to Section 2.2, prorated based on the number of days Employee was actively employed by the Company during such year (or in the case of the 2015 Bonus, the period from the Date of Hire through
December 31, 2015), payable at the time such Performance Bonus or 2015 Bonus would otherwise be paid in accordance with such Section 2.2, (iv) continued participation in the Plans pursuant to Section 2.4 for the duration of the
Severance Period to the extent such continued participation is permitted under the terms of the Plans and to the extent such participation is not permitted a cash payment of substantially similar value (without requiring any additional payments to
address the taxability of this payment), (v) reimbursement of expenses to which Employee is otherwise entitled under Sections 2.4, 2.5 or 2.8 hereof, and (vi) whatever rights as to stock options or other equity awards the Employee may
have pursuant to the 2015 Option Agreement, the Matching PRSU Agreement, the Project 650 PRSU Agreement or the Base RSU Agreement or any other stock option agreements or other equity award agreements with the Company. 

(b) Section 3.1(c) (Termination by Company for Cause) and 3.1(d) (Termination upon Death or Disability) Terminations;
Voluntary Termination by Employee not for Good Reason. If Employee’s employment is terminated pursuant to Sections 3.1(c) or 3.1(d) hereof, or if Employee quits employment (other than for Good Reason) notwithstanding the terms of this
Agreement, Employee or Employee’s estate shall have no further rights against the Company hereunder, except for the right to receive, subject to execution of a Release and Waiver in the case of clauses (iii), (x), (y) and (z) below,
(i) any earned but unpaid Base Salary and the value of any accrued but unused vacation, (ii) reimbursement of expenses to which Employee is entitled under Sections 2.4, 2.5 or 2.8 hereof, and (iii) in the case of a termination
pursuant to Section 3.1(d) hereof, (x) any previously earned Performance Bonus for a prior Bonus Year, or any 2015 Bonus, which has not been paid, (y) any annual Performance Bonus or 2015 Bonus due for the calendar year of such
termination pursuant to Section 2.2, prorated based on the number of days Employee was actively employed by the Company during such year (or in the case of the 2015 Bonus, the period from the Date of Hire through December 31, 2015),
payable at the time the such Performance Bonus or 2015 Bonus would otherwise be paid in accordance with such Section 2.2, and (z) whatever rights as to stock options or other equity awards Employee may have pursuant to the 2015 Option
Agreement, the Matching PRSU Agreement, the Project 650 PRSU Agreement, Base RSU Agreement or any other stock option agreements or other equity award agreements with the Company. 

(c) Non-Renewal. In the event that the Company elects not to renew the term of this Agreement as provided in Section 1.1, or if
Employee elects not to renew the term of this Agreement as provided in Section 1.1, then Employee shall have no 

  
 7 

 
further rights against the Company hereunder, except for the right to receive, subject to execution of a Release and Waiver in the case of clauses (iii), (x), (y) and (z) below,
(i) any earned but unpaid Base Salary and the value of any accrued but unused vacation, (ii) reimbursement of expenses to which Employee is entitled under Sections 2.4, 2.5 or 2.8 hereof, and (iii) (x) any previously earned
Performance Bonus for a prior Bonus Year which has not been paid, (y) any annual Performance Bonus due for the calendar year in which the non-renewal occurs, prorated based on the number of days Employee was actively employed by the
Company during such year, payable at the time the such Performance Bonus would otherwise be paid in accordance with such Section 2.2, and (z) whatever rights as to stock options or other equity awards Employee may have pursuant to the 2015
Option Agreement, the Matching PRSU Agreement, the Project 650 PRSU Agreement, Base RSU Agreement or any other stock option agreements or other equity award agreements with the Company. 

(d) The Release and Waiver described in Sections 3.2(a), (b) and (c) shall be delivered to Employee on or before the fourteenth (14th) day following separation from employment with the Company. In addition and notwithstanding the foregoing provisions of this Section 3.2, if the Release and Waiver described in
Section 3.2(a), 3.2(b) or 3.2(c), as applicable, has been delivered to Employee within fourteen (14) days following separation from employment but has not been executed and delivered and become irrevocable on or before the end of the sixty
(60) day period following Employee’s termination of employment with the Company, no severance benefits under Section 3.2(a)(ii)-(iv) and (vi) or Section 3.2(b)(iii), (x), (y) and (z) or
Section 3.2(c)(iii) (x), (y) and (z), as applicable, shall be or become payable. Further, to the extent that (A) such termination of employment occurs within sixth (60) days of the end of any calendar year, and (B) any of
such severance benefits constitute “nonqualified deferred compensation” for purposes of Section 409A of the Code, any payment of any amount or provision of any benefit otherwise scheduled to occur prior to the sixtieth (60th) day following the date of Employee’s termination of employment hereunder, but for the condition on executing the severance release as set forth herein, shall be made (or commence being
made) on the later of January 15th of the next calendar year following termination of employment or the date such release and waiver is delivered and has become irrevocable, after which any
remaining severance benefits shall thereafter be provided to Employee without interest according to the applicable schedule set forth herein. 

ARTICLE IV 

CONFIDENTIALITY; NON-COMPETITION; NON-SOLICITATION 

4.1 Covenants Regarding Confidential Information, Trade Secrets and Other Matters. Employee covenants and agrees as follows: 

(a) Definitions. For purposes of this Agreement, the following terms are defined as follows: 

(1) “Trade Secret” means all information possessed by or developed for the Company or any of its subsidiaries, including,
without limitation, a compilation, program, device, method, system, technique or process, to which all of the following apply: (i) the information derives independent economic value, actual or potential, from not being generally known to, and

  
 8 

 
not being readily ascertainable by proper means by, other persons who can obtain economic value from its disclosure or use and (ii) the information is the subject of efforts to maintain its
secrecy that are reasonable under the circumstances. 
 (2) “Confidential Information” means information, to the extent it
is not a Trade Secret, which is possessed by or developed for the Company or any of its subsidiaries and which relates to the Company’s or any of its subsidiaries’ existing or potential business or technology, which information is
generally not known to the public and which information the Company or any of its subsidiaries seeks to protect from disclosure to its existing or potential competitors or others, including, without limitation, for example: business plans,
strategies, existing or proposed bids, costs, technical developments, existing or proposed research projects, financial or business projections, investments, marketing plans, negotiation strategies, training information and materials, information
generated for client engagements and information stored or developed for use in or with computers. Confidential Information also includes information received by the Company or any of its subsidiaries from others which the Company or any of its
subsidiaries has an obligation to treat as confidential. 
 (b) Nondisclosure of Confidential Information. Except as required in the
conduct of the Company’s or any of its subsidiaries’ business or as expressly authorized in writing on behalf of the Company or any of its subsidiaries, Employee shall not use or disclose, directly or indirectly, any Confidential
Information during the period of his employment with the Company. In addition, following the termination for any reason of Employee’s employment with the Company, Employee shall not use or disclose, directly or indirectly, any Confidential
Information. This prohibition does not apply to Confidential Information after it has become generally known in the industry in which the Company conducts its business. This prohibition also does not prohibit Employee’s use of general skills
and know-how acquired during and prior to employment by the Company, as long as such use does not involve the use or disclosure of Confidential Information or Trade Secrets. 

(c) Trade Secrets. During Employee’s employment by the Company, Employee shall do what is reasonably necessary to prevent
unauthorized misappropriation or disclosure and threatened misappropriation or disclosure of the Company’s or any of its subsidiaries’ Trade Secrets and, after termination of employment, Employee shall not use or disclose the
Company’s or any of its subsidiaries’ Trade Secrets as long as they remain, without misappropriation, Trade Secrets. 
 (d)
Copyright. All copyrightable work by Employee relating to the Company’s business or the business of any subsidiary or affiliate of the Company during the term of Employee’s employment by the Company is intended to be “work made
for hire” as defined in Section 101 of the Copyright Act of 1976, and shall be the property of the Company. If the copyright to any such copyrightable work is not the property of the Company by operation of law, Employee will, without
further consideration, assign to the Company all right, title and interest in such copyrightable work and will assist the Company and its nominee in every way, at the Company’s expense, to secure, maintain and defend for the Company’s
benefit, copyrights and any extensions and renewals thereof on any and all such work including translations thereof in any and all countries, such work to be and remain the property of the Company whether copyrighted or not. 

  
 9 

 (e) Exceptions. The provisions of paragraphs (b) and (c) above will not be
deemed to prohibit any disclosure that is required by law or court order, provided that Employee has not intentionally taken actions to trigger such required disclosure and the Company is given reasonable prior notice and an opportunity to contest
or minimize such disclosure. 
 4.2 Non-Competition. 

(a) During Employment. During Employee’s employment hereunder, Employee shall not engage, directly or indirectly, as an employee,
officer, director, partner, manager, consultant, agent, owner (other than a minority shareholder or other equity interest of not more than 1% of a company whose equity interests are publicly traded on a nationally recognized stock exchange or
over-the-counter) or in any other capacity, in any competition with the Company or any of its subsidiaries. 
 (b) Subsequent to
Employment. For a two (2) year period following the termination of Employee’s employment for any reason or without reason, Employee shall not in any capacity (whether in the capacity as an employee, officer, director, partner, manager,
consultant, agent or owner (other than a minority shareholder or other equity interest of not more than 1% of a company whose equity interests are publicly traded on a nationally recognized stock exchange or over-the-counter)), directly or
indirectly advise, manage, render or perform services to or for (i) any person or entity which is engaged in a business competitive to that of the Company or any of its subsidiaries (including without limitation those businesses listed in
Appendix A to the form of 2015 Option Agreement attached hereto as Exhibit B) within any geographical location wherein the Company or any of its subsidiaries produces, sells or markets its goods and services at the time of such
termination or within a one-year period prior to such termination or (ii) any Significant Retailer. For purposes of this Agreement, “Significant Retailer” means those retailers identified in Exhibit B under the
heading “RETAILERS.” Employee acknowledges that the Significant Retailers may now or in the future compete directly or indirectly with the Company, and that, whether or not a Significant Retailer competes directly with the Company, the
Employee because of his knowledge of the industry and his knowledge of confidential information about the Company’s commercial relationships with many large retailers, including one or more of the Significant Retailers, could damage the
Company’s competitive position and business if he worked with a Significant Retailer in any of the capacities described above. 
 4.3
Non-Solicitation. For a two (2) year period following the termination of Employee’s employment for any reason or without reason, Employee shall not solicit or induce any person who was an employee of the Company or any of its
subsidiaries on the date of Employee’s termination, or within three (3) months prior to leaving his or her employment with the Company or any of its subsidiaries, to leave the employ of the Company or its subsidiaries. 

4.4 Return of Documents. Immediately upon termination of employment, Employee will return to the Company, and so certify in writing to
the Company, all the Company’s or any of its subsidiaries’ papers, documents and things, including information 

  
 10 

 
stored for use in or with computers and software applicable to the Company’s and its subsidiaries’ business (and all copies thereof), which are in Employee’s possession or under
Employee’s control, regardless whether such papers, documents or things contain Confidential Information or Trade Secrets. 
 4.5 No
Conflicts. To the extent that they exist, Employee will not disclose to the Company or any of its subsidiaries any of Employee’s previous employer’s confidential information or trade secrets. Further, Employee represents and warrants
that Employee has not previously assumed any obligations inconsistent with those of this Agreement and that employment by the Company does not conflict with any prior obligations to third parties. In addition, Employee and the Company agree that it
is important for any prospective employer to be aware of this Agreement, so that disputes concerning this Agreement can be avoided in the future. Therefore, Employee agrees that, following termination of employment with the Company, the Company may
forward a copy of Article IV of this Agreement (and any related Exhibits hereto) to any future prospective or actual employer, and Employee releases the Company from any claimed liability or damage caused to Employee by virtue of the Company’s
act in making that prospective or actual employer aware of Article IV of this Agreement (and any related Exhibits hereto). 
 4.6
Agreement on Fairness. Employee acknowledges that: (i) this Agreement has been specifically bargained between the parties and reviewed by Employee, (ii) Employee has had an opportunity to obtain legal counsel to review this
Agreement, and (iii) the covenants made by and duties imposed upon Employee hereby are fair, reasonable and minimally necessary to protect the legitimate business interests of the Company, and such covenants and duties will not place an undue
burden upon Employee’s livelihood in the event of termination of Employee’s employment by the Company and the strict enforcement of the covenants contained herein. 

4.7 Equitable Relief and Remedies. Employee acknowledges that any breach of this Agreement will cause substantial and irreparable harm
to the Company for which money damages would be an inadequate remedy. Accordingly, notwithstanding the provisions of Article V below, the Company shall in any such event be entitled to obtain injunctive and other forms of equitable relief to
prevent such breach and the prevailing party shall be entitled to recover from the other, the prevailing party’s costs (including, without limitation, reasonable attorneys’ fees) incurred in connection with enforcing this Agreement, in
addition to any other rights or remedies available at law, in equity, by statute or pursuant to Article V below. 
 ARTICLE V 

AGREEMENT TO SUBMIT ALL EXISTING OR FUTURE DISPUTES 

TO BINDING ARBITRATION 

The Company and Employee agree that any controversy or claim arising out of or related to this Agreement or Employee’s employment with or
termination by the Company that is not resolved by the parties shall be settled by arbitration administered by the American Arbitration Association under its National Rules for the Resolution of Employment Disputes. Any such arbitration shall be
conducted in Lexington, Kentucky. The parties further agree that the arbitrator may resolve issues of contract interpretation as well as 

  
 11 

 
law and award damages, if any, to the extent provided by this Agreement or applicable law. The parties agree that the costs of the arbitrator’s services shall be borne by the Company. The
parties further agree that the arbitrator’s decision will be final and binding and enforceable in any court of competent jurisdiction. In addition to the A.A.A.’s Arbitration Rules and unless otherwise agreed to by the parties, the
following rules shall apply: 
 (a) Each party shall be entitled to discovery exclusively by the following means: (i) requests for
admission, (ii) requests for production of documents, (iii) up to fifteen (15) written interrogatories (with any subpart to be counted as a separate interrogatory), and (iv) depositions of no more than six (6) individuals.

 (b) Unless the arbitrator finds that delay is reasonably justified or as otherwise agreed to by the parties, all discovery shall be
completed, and the arbitration hearing shall commence, within five (5) months after the appointment of the arbitrator. 
 (c) Unless
the arbitrator finds that delay is reasonably justified, the hearing will be completed, and an award rendered, within thirty (30) days of commencement of the hearing. 

The arbitrator’s authority shall include the ability to render equitable types of relief and, in such event, any aforesaid court may
enter an order enjoining and/or compelling such actions or relief ordered or as found by the arbitrator. 
 Each party shall bear its own
legal and other professional fees and costs incurred in connection with such arbitration proceeding and any necessary court action. 

Notwithstanding the foregoing provisions of this Article V, the parties expressly agree that a court of competent jurisdiction may enter a
temporary restraining order or an order enjoining a breach of Article IV of this Agreement without submission of the underlying dispute to an arbitrator. Such remedy shall be cumulative and nonexclusive, and shall be in addition to any other remedy
to which the parties may be entitled. 
 ARTICLE VI 

GENERAL PROVISIONS 
 6.1
Notices. Any and all notices provided for in this Agreement shall be given in writing and shall be deemed given to a party at the earlier of (i) when actually delivered to such party, or (ii) when mailed to such party by registered
or certified mail (return receipt requested) or sent to such party by courier, confirmed by receipt, and addressed to such party at the address designated below for such party as follows (or to such other address for such party as such party may
have substituted by notice pursuant to this Section 6.1): 
  

					
		 	(a) If to the Company:	  	 Tempur Sealy International, Inc.

		 		  	 1000 Tempur Way

		 		  	 Lexington, KY 40511

			
		 		  	Attention: Board of Directors
			
		 		  	 with a copy to Executive Vice President

and General Counsel

  
 12 

					
		 	(b) If to Employee:	  	Scott Thompson
		 		  	c/o Tempur Sealy International, Inc.
		 		  	1000 Tempur Way
		 		  	Lexington, KY 40511

 6.2 Entire Agreement; Survival. This Agreement contains the entire understanding and the full and
complete agreement of the parties and supersedes and replaces any prior understandings and agreements among the parties with respect to the subject matter hereof. The provisions of this Agreement shall survive the termination of the Agreement, or of
Employee’s employment for any reason, to the extent necessary to enable the parties to enforce their respective rights. 
 6.3
Amendment; Headings and References. This Agreement may be altered, amended or modified only in writing, signed by both of the parties hereto, except that either party may update its address set forth in Section 6.1 by providing a notice
of the updated address in the manner set forth in Section 6.1. Headings included in this Agreement are for convenience only and are not intended to limit or expand the rights of the parties hereto. References to Sections herein shall mean
sections of the text of this Agreement, unless otherwise indicated. 
 6.4 Assignability. This Agreement and the rights and duties
set forth herein may not be assigned by either of the parties without the express written consent of the other party. This Agreement shall be binding on and inure to the benefit of each party and such party’s respective heirs, legal
representatives, successors and assigns. 
 6.5 Severability. If any court of competent jurisdiction determines that any provision of
this Agreement is invalid or unenforceable, then such invalidity or unenforceability shall have no effect on the other provisions hereof, which shall remain valid, binding and enforceable and in full force and effect, and such invalid or
unenforceable provision shall be construed in a manner so as to give the maximum valid and enforceable effect to the intent of the parties expressed therein. 

6.6 Waiver of Breach. The waiver by either party of the breach of any provision of this Agreement shall not operate or be construed as
a waiver of any subsequent breach by either party. 
 6.7 Governing Law; Jurisdiction; Construction. This Agreement shall be governed
by the internal laws of the Commonwealth of Kentucky, without regard to any rules of construction that would require application of the laws of another jurisdiction. Any legal proceeding related to this Agreement and permitted under Section 4.7
and Article V hereof must be litigated in an appropriate Kentucky state or federal court, and both the Company and Employee hereby consent to the exclusive jurisdiction of the Commonwealth of Kentucky for this purpose; waive any objection they may
now or hereafter have to venue or to convenience of 

  
 13 

 
forum and agree that all legal proceedings will be tried in a court of competent jurisdiction by a judge without a jury. The parties hereto agree that they have been represented by counsel during
the negotiation and execution of this Agreement and, accordingly each party waives the application of any law, holding or rule of construction providing that ambiguities in an agreement or other document will be construed against the party drafting
such agreement or document. 
 6.8. Tax Compliance. 

(a) The Company may withhold from any amounts payable hereunder any amounts required to be withheld under federal, state or local law and any
other deductions authorized by Employee. The Company and Employee agree that they will execute any and all amendments to this Agreement as they mutually agree in good faith may be necessary to ensure compliance with the provisions of
Section 409A (together with any implementing regulations, “Section 409A”) of the Code while preserving insofar as possible the economic intent of the respective provisions, so that Employee will not be subject to any tax
(including interest and penalties) under Section 409A. 
 (b) For purposes of Section 409A, the right to a series of installment
payments under this Agreement shall be treated as a right to a series of separate payments. 
 (c) With respect to any reimbursement of
expenses of, or any provision of in-kind benefits to, Employee, as specified under this Agreement, such reimbursement of expenses or provision of in-kind benefits shall be subject to the following conditions: (1) the expenses eligible for
reimbursement or the amount of in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other taxable year, except for any medical reimbursement
arrangement providing for the reimbursement of expenses referred to in Section 105(b) of the Code; (2) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which such expense was
incurred; and (3) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit. 

(d) Notwithstanding anything to the contrary in this Agreement, if Employee is a “specified employee” as determined pursuant to
Section 409A as of the date of Employee’s “separation from service” as defined in Treasury Regulation Section 1.409A-1(h) (or any successor regulation) and if any payments or
entitlements provided for in this Agreement constitute a “deferral of compensation” within the meaning of Section 409A and cannot be paid or provided in the manner provided herein without subjecting Employee to additional tax,
interest or penalties under Section 409A, then any such payment or entitlement which is payable during the first six (6) months following Employee’s “separation from service” shall be paid or provided to Employee in a cash
lump-sum on the first business day of the seventh (7th) calendar month immediately following the month in which Employee’s “separation from service” occurs or, if earlier, upon Employee’s death. In addition, any payments or
benefits due hereunder upon a termination of Employee’s employment which are a “deferral of compensation” within the meaning of Section 409A shall only be payable or provided to Employee (or Employee’s estate) upon a
“separation from service” as defined in Section 409A. Finally, for the purposes of this Agreement, amounts payable under Section 3.2 shall be deemed not to be a “deferral of compensation” subject to

  
 14 

 
Section 409A to the extent provided in the exceptions in Treasury Regulation Sections 1.409A-1(b)(4) (“short-term deferrals”) and (b)(9) (“separation pay plans,”
including the exception under subparagraph (iii)) and other applicable provisions of Treasury Regulation Section 1.409A-1 – A-6. 

(e) Whenever a payment under this Agreement specifies a payment period with reference to a number of days (for example, “payment shall
be made within thirty (30) days following the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of the Company. In no event may Employee, directly or indirectly,
designate the calendar year of any payment to be made under this Agreement, to the extent such payment is subject to Code Section 409A. 

(f) The Company makes no representation or warranty and shall have no liability to Employee or any other person if any provisions of this
Agreement are determined to constitute deferred compensation subject to Code Section 409A but do not satisfy an exemption from, or the conditions of, Code Section 409A. 

(g) Limitation on Payments and Benefits. Notwithstanding any provision of this Agreement to the contrary, in the event that any amount
or benefit to be paid or provided under this Agreement or otherwise to the Employee constitutes a “parachute payment” within the meaning of Section 280G of the Code, and but for this provision, would be subject to the excise tax
imposed by Section 4999 of the Code, then the totality of those amounts shall be either: (a) delivered in full, or (b) delivered as to such lesser extent which would result in no portion of such payments and benefits being subject to
excise tax under Section 4999 of the Code, whichever of the foregoing amounts, taking into account the applicable federal, state and local income and employment taxes and the excise tax imposed by Section 4999 of the Code (and any
equivalent state or local excise taxes), results in the receipt by the Employee on an after-tax basis, of the greatest amount of such payments and benefits, notwithstanding that all or some portion of such amount may be taxable under
Section 4999 of the Code. Unless the Company and the Employee otherwise agree, any determination required under this provision shall be made in writing by a firm of independent public accountants or a law firm selected by the Company and
reasonably acceptable to the Employee (the “Accountants”), whose determination shall be conclusive and binding upon the Employee and the Company for all purposes. The Company and the Employee agree to furnish to the Accountants such
information and documents as the Accountants may reasonably request in order to make a determination under this provision. The Company will bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this
provision. Any reduction of any amount required by this provision shall occur in the following order: (1) reduction of cash payments to the Employee under this Agreement or otherwise; (2) reduction of vesting acceleration of equity awards
under this Agreement or otherwise; and (3) reduction of other benefits paid or provided to the Employee. If two or more equity awards are granted on the same date, each award will be reduced on a pro rata basis (dollar-for-dollar). 

6.9. Expenses. The Company agrees to reimburse Employee for the reasonable and documented fees and expenses of Employee’s legal
counsel in connection with the negotiation and preparation of this Agreement, in an amount not to exceed $20,000. 

  
 15 

 6.10. Indemnification; Insurance Coverage. The Company’s By-Laws, as may be amended
from time to time, provide to directors and executive officers of the Company certain rights to indemnification by the Company and to directors and officers insurance coverage. Employee shall be entitled to the same level of protection provided to
executive officers and, as applicable, directors, as contemplated in the Company’s By-Laws, as may be amended from time to time. 

[Remainder of Page Intentionally Left Blank] 

  
 16 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year
written above. 
  

			
	COMPANY:
	
	TEMPUR SEALY INTERNATIONAL, INC.
	
	 /s/ Frank Doyle

	By:	 	Frank Doyle
	Title:	 	Chairman of the Board of Directors
	
	EMPLOYEE:
	
	 /s/ Scott Thompson

	Scott Thompson
	
	WITNESSED BY:
	
	 /s/ Vanessa Thompson

	Name:	 	Vanessa Thompson

 Date: September 4, 2015 

  
 [Signature Page to
Employment and Non-Competition Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00249-of-00352.parquet"}]]